COMMUNIQUÉS West-GlobeNewswire

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21/06/2024
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen [...]
Trading by management and close relations of management
21/06/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Major shareholder announcement
21/06/2024
June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary [...]
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
21/06/2024
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
21/06/2024
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Paris, June 21, 2024 . Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President [...]
Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi
21/06/2024
Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi Paris, le 21 juin 2024 . Audrey Duval Derveloy, leader chevronnée du secteur de la santé et Présidente de Sanofi [...]
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
21/06/2024
Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category ‘ [...]
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
21/06/2024
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class [...]
Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie
21/06/2024
ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie Sept communications orales dédiées au portefeuille Hémophilie illustrent la volonté de [...]
Radiopharm Receives Strategic Investment for up to A$18 million
21/06/2024
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option [...]
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
20/06/2024
All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, June 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company [...]
Cellectis publie un article scientifique dévoilant trois facteurs clés pour une édition efficace avec des TALE base editors
20/06/2024
NEW YORK, 20 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
20/06/2024
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/06/2024
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
20/06/2024
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, [...]
Tilray Medical lance la marque de cannabis thérapeutique Broken Coast en Australie
20/06/2024
Les fleurs entières de cannabis médical Broken Coast, certifiées BPF-UE, sont désormais disponibles sur prescription médicale en Australie NEW YORK et SYDNEY, 20 juin 2024 (GLOBE NEWSWIRE) -- Tilray Medical, une [...]
$1.1 million for new brain injury research in Canada
20/06/2024
Brain Canada and Brain Changes Initiative (BCI) to support innovative projects that will address some of the most pressing issues in TBI MONTREAL, June 20, 2024 (GLOBE NEWSWIRE) -- It is estimated that approximately 165 [...]
1,1 M$ pour de nouvelles recherches sur les lésions cérébrales au Canada
20/06/2024
La Fondation Brain Canada et Brain Changes Initiative (BCI) appuieront des projets novateurs qui aborderont certaines des questions les plus pressantes en matière de TCC MONTRÉAL, 20 juin 2024 (GLOBE NEWSWIRE) -- Chaque [...]
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
20/06/2024
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Body weight reductions [...]

Pages